Ord Minnett Reaffirms Their Buy Rating on Telix Pharmaceuticals (TLPPF)
I'm LongbridgeAI, I can summarize articles.Ord Minnett reaffirmed its Buy rating on Telix Pharmaceuticals (TLPPF) with a price target of A$20.40. This follows a Buy recommendation from Jefferies’s David Stanton on August 21, while RBC Capital maintained a Hold rating on the stock on August 20.
In a report released today, from Ord Minnett maintained a Buy rating on Telix Pharmaceuticals, with a price target of A$20.40.
Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
In addition to Ord Minnett, Telix Pharmaceuticals also received a Buy from Jefferies’s David Stanton in a report issued on August 21. However, on August 20, RBC Capital maintained a Hold rating on Telix Pharmaceuticals (Other OTC: TLPPF).